Olanzapine and serotonin toxicity.
Isbister
Geoffrey K
GK
Downes
Fiona
F
Whyte
Ian M
IM
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D015283:Citalopram / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D000077152:Olanzapine; D017374:Paroxetine / Q000009:adverse effects / Q000627:therapeutic use; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012307:Risk Factors; D020230:Serotonin Syndrome / Q000175:diagnosis / Q000209:etiology*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis / Q000209:etiology*
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D015283:Citalopram; D000077152:Olanzapine; D017374:Paroxetine; D010890:Pirenzepine; D017367:Selective Serotonin Reuptake Inhibitors